Medivir AB (MVIRb.F): Data from Simeprevir in Hepatitis C Patients Will be Presented at EASL During 24-28 April in Amsterdam  
4/8/2013 6:49:58 AM

Medivir AB (OMX: MVIR) (STO:MVIR-B) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands.